NasdaqGS - Nasdaq Real Time Price USD

Amphastar Pharmaceuticals, Inc. (AMPH)

24.20
+0.04
+(0.17%)
At close: 4:00:01 PM EDT
24.20
0.00
(0.00%)
After hours: 4:20:00 PM EDT
Loading Chart for AMPH
  • Previous Close 24.16
  • Open 23.94
  • Bid 24.18 x 100
  • Ask 24.28 x 100
  • Day's Range 23.93 - 24.38
  • 52 Week Range 22.64 - 53.96
  • Volume 342,596
  • Avg. Volume 637,174
  • Market Cap (intraday) 1.141B
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) 8.77
  • EPS (TTM) 2.76
  • Earnings Date Aug 5, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 32.40

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

www.amphastar.com

2,028

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AMPH

View More

Performance Overview: AMPH

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AMPH
34.82%
S&P 500 (^GSPC)
0.67%

1-Year Return

AMPH
44.32%
S&P 500 (^GSPC)
10.08%

3-Year Return

AMPH
28.19%
S&P 500 (^GSPC)
49.74%

5-Year Return

AMPH
30.53%
S&P 500 (^GSPC)
97.67%

Compare To: AMPH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AMPH

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    1.14B

  • Enterprise Value

    1.55B

  • Trailing P/E

    8.75

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.70

  • Price/Book (mrq)

    1.52

  • Enterprise Value/Revenue

    2.13

  • Enterprise Value/EBITDA

    6.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.38%

  • Return on Assets (ttm)

    7.60%

  • Return on Equity (ttm)

    19.90%

  • Revenue (ttm)

    730.66M

  • Net Income Avi to Common (ttm)

    141.63M

  • Diluted EPS (ttm)

    2.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    236.88M

  • Total Debt/Equity (mrq)

    86.86%

  • Levered Free Cash Flow (ttm)

    -3.71M

Research Analysis: AMPH

View More

Company Insights: AMPH

Research Reports: AMPH

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.